ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for Alzheimer's disease (AD). ELND005 may prevent or inhibit the build up of amyloid protein in the brains of Alzheimer's disease patients.

Clinical Trial Design


• Randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study
• 250, 1000, 2000 mg bid ELND005 vs. placebo
• Approximately 340 participants aged 50-85 years with mild to moderate AD
• 62 clinical sites across North America
• Protocol modified in December 2009
   - Discontinued 1000 and 2000 mg bid
   - 250 mg and placebo to continue
   - Last patient last visit in April 2010
• Status: COMPLETED (Aug 2010) - Link to press release

Primary Outcome Measures

• Safety and tolerability
• Cognitive and functional measures